October 07, 2015
A prescription for hope
BY Laura Sussman
拉斐尔·潘托哈已经几乎失去了希望。
他14年的斗争甲状腺癌是背部和蔓延。
Then, earlier this year, he began taking lenvatinib, a drug that was tested at MD Anderson and approved by the食品和药物管理局（FDA）二月。Lenvatinib对待病人如潘托哈，其甲状腺癌不向更传统的放射性碘治疗的反应。它使用定向辐射销毁仍然后甲状腺手术，取出任何甲状腺组织或癌细胞。
几十年来，标准治疗是施用重复和往往是无效的剂量放射性碘，有时化疗，”说史蒂文•谢尔曼医学博士，副副教务长的临床研究。188bet体育网址“大约10年前，随着新的科学发现，我们开始认识到用药物治疗的患者的潜力，从不断壮大自己的血管停止肿瘤。”
That’s exactly how lenvatinib works. A global study of the drug, also known as Lenvima, demonstrated a dramatic improvement in progression-free survival, with a 65% response rate.
“这些是甲状腺癌患者的这种疾病晚期前所未有的效果，”谢尔曼，谁领导了这项研究说。
Results fromthe study发表在新英格兰医学杂志的，与药物的FDA的批准相符。Mouhammed Habra, M.D.，副教授内分泌肿瘤和荷尔蒙失调，领导这项研究的相III成分在MD安德森。
Pantoja, who has been under the care of史蒂芬Waguespack，医学博士, professor of Endocrine Neoplasia and Hormonal Disorders (pictured above), directly benefited as a result of the clinical trials. So far, he hasn’t experienced many of the side effects that sometimes accompany the drug, including diarrhea, fatigue, nausea and weight loss. He is, however, among the 40% of patients whose blood pressure rises after taking Lenvima. He’s now on medication to keep his blood pressure in check.
“Lenvima似乎是工作，”潘托哈，谁经历了几次手术癌细胞扩散后，除去他的手臂骨头的部分说。“我已经看到甲状腺球蛋白减少了75％。”
在甲状腺球蛋白的下降 - 通过正常和癌变甲状腺组织产生的蛋白质 - 通常是为先进的甲状腺癌正在接受治疗的患者的好消息。
阅读潘托哈的全文here。